<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "irinotecan inj VIAL>
<dose><value>165</value>
<value>350</value>
<value>280</value>
<value>250</value>
<value>180</value>
</dose><route><value>IV</value>
</route><form><value>inj VIAL</value>
</form><drug><value>irinotecan inj VIAL</value>
</drug><strength><value>20 mg/mL</value>
</strength><frequency><value>ONCE</value>
</frequency><instruction><value>Administer dose diluted in 500 mL D5W over 90 minutes.</value>
</instruction><volume><value>2 mL</value>
<value>5 mL</value>
</volume><units><value>mg/m2</value>
</units><additionalnotes><value>Metastatic Colorectal Cancer</value>
<value>Metastatic Colorectal Cancer. For patients 70 years or older, or in patients with prior pelvic RT, start dose at 80%.</value>
<value>Metastatic Colorectal Cancer. 80% dose of 350 mg/m2; suggested for patients 70 years or older, or in patients with prior pelvic RT.</value>
<value>Metastatic Colorectal Cancer.</value>
<value>Metastatic Colorectal Cancer, Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer, Metastatic Pancreatic Cancer. Dose to run concurrently with leucovorin order (FOLFIRI protocol).</value>
</additionalnotes><population><value>ADULT</value>
</population><indicationprn><value></value>
</indicationprn><backgroundinformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3404</value>
</backgroundinformation><prninformation><value></value>
</prninformation><ahsformularystatus><value>Formulary.</value>
</ahsformularystatus><ahfsname><value>Antineoplastic Agents</value>
</ahfsname><highalert><value>YES</value>
</highalert><maximumprndose><value>YES</value>
</maximumprndose></drug>